Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 767 Lung Neoplasms 340 Ovarian Neoplasms 318 Breast Neoplasms 277 Fallopian Tube Neoplasms 158 Triple Negative Breast Neoplasms 144 Small Cell Lung Carcinoma 142 Neoplasms 134 Squamous Cell Carcinoma of Head and Neck 122 Carcinoma, Ovarian Epithelial 114 Neoplasm Metastasis 85 Head and Neck Neoplasms 80 Endometrial Neoplasms 77 Esophageal Neoplasms 71 Uterine Cervical Neoplasms 70 Adenocarcinoma of Lung 69 Neuroblastoma 55 Central Nervous System Neoplasms 52 Carcinoma 50 Lymphoma, Large B-Cell, Diffuse 49 Brain Neoplasms 48 Recurrence 47 Prostatic Neoplasms 44 Parkinson Disease 4, Autosomal Dominant Lewy Body 44 Urinary Bladder Neoplasms 42 Esophageal Squamous Cell Carcinoma 41 Lymphoma 39 Melanoma 35 Carcinoma, Squamous Cell 33 Lymphoma, Non-Hodgkin 31

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × Carboplatin × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡